121 related articles for article (PubMed ID: 8462128)
1. Oral bioavailability of mesna tablets.
Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
[TBL] [Abstract][Full Text] [Related]
2. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
James CA; Mant TG; Rogers HJ
Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
[TBL] [Abstract][Full Text] [Related]
5. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
Roth B; Cerny T; Brunner KW; Küpfer A
Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of orally administered mesna.
Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
[TBL] [Abstract][Full Text] [Related]
7. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
Shaw IC; Weeks MS
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
[TBL] [Abstract][Full Text] [Related]
8. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
Goren MP; Anthony LB; Hande KR; Johnson DH; Brade WP; Frazier MW; Bush DA; Li JT
J Clin Oncol; 1998 Feb; 16(2):616-21. PubMed ID: 9469350
[TBL] [Abstract][Full Text] [Related]
10. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
Jones MS; Murrell RD; Shaw IC
Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: a comparison between MESNA and ARGIMESNA.
Pea F; Mazzo M; Miglioli PA; Casiglia E; Pessina A; Moretti V
Pharmacol Res; 1992; 25 Suppl 1():85-6. PubMed ID: 1508821
[No Abstract] [Full Text] [Related]
13. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
el-Yazigi A; Yusuf A; al-Rawithi S
Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
[TBL] [Abstract][Full Text] [Related]
14. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
15. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
16. Depletion of circulating cyst(e)ine by oral and intravenous mesna.
Stofer-Vogel B; Cerny T; Küpfer A; Junker E; Lauterburg BH
Br J Cancer; 1993 Sep; 68(3):590-3. PubMed ID: 8353049
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of mesna with ifosfamide.
Goren MP
Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
[TBL] [Abstract][Full Text] [Related]
18. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
19. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Verschraagen M; Zwiers TH; de Koning PE; Welink J; van der Vijgh WJ
J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):293-302. PubMed ID: 11334343
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS].
Xia T; Liu DD; Shi LF; Hu JH
Yao Xue Xue Bao; 2011 Aug; 46(8):951-4. PubMed ID: 22007521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
